Stockscreener 앱 받기
45.06
0.83%
0.3674
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Xenon Pharmaceuticals stock hits 52-week high at 45.09 USD By Investing.com - Investing.com South Africa
Xenon Pharmaceuticals Reports Significant Long-Term Efficacy of Azetukalner in Epilepsy at AES 2025 - Quiver Quantitative
Saturn V Capital Management LP Boosts Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - TipRanks
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
How Xenon Pharmaceuticals Inc. stock performs in rate cut cyclesJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares By Investing.com - Investing.com South Africa
Ian Mortimer, Xenon Pharma CEO, sells $4365 in shares - Investing.com
Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? - Yahoo Finance
Xenon Pharmaceuticals to Host Webinar on Epilepsy Data and Commercialization Plans - TipRanks
Xenon (Nasdaq: XENE) sets AES 2025 webinar on azetukalner epilepsy data, commercialization - Stock Titan
JPMorgan Chase & Co. Cuts Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Loomis Sayles & Co. L P Sells 15,846 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
American Century Companies Inc. Takes Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Expands 2025 Equity Incentive Plan - TipRanks
(XENE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Ameritas Investment Partners Inc. Acquires Shares of 7,758 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Geode Capital Management LLC Purchases 900,746 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals (XENE): Evaluating Valuation as New Epilepsy and Dravet Data Draw Investor Attention - Sahm
Xenon Reports Second Quarter 2025 Financial Results & Business Update - ADVFN
Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 52-Week HighTime to Buy? - MarketBeat
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD By Investing.com - Investing.com Nigeria
Xenon Pharmaceuticals stock hits 52-week high at 44.58 USD - Investing.com
Xenon Pharmaceuticals to Present New Epilepsy Research at AES 2025 - TipRanks
Xenon Pharmaceuticals to Present New Data on Azetukalner and Epilepsy at American Epilepsy Society Annual Meeting 2025 - Quiver Quantitative
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025 - Caledonian Record
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? - sharewise.com
FY2025 Earnings Estimate for XENE Issued By Chardan Capital - Defense World
Is Xenon Pharmaceuticals Inc. stock a dividend growth opportunityQuarterly Profit Report & Daily Profit Focused Screening - newser.com
Envestnet Asset Management Inc. Decreases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - Defense World
How Xenon Pharmaceuticals Inc. stock performs during Fed tightening cyclesQuarterly Performance Summary & AI Powered Buy and Sell Recommendations - newser.com
Why Xenon Pharmaceuticals Inc. stock is recommended by analystsPortfolio Profit Report & Long-Term Growth Plans - newser.com
Why Xenon Pharmaceuticals Inc. stock could outperform in 2025Trend Reversal & AI Enhanced Execution Alerts - newser.com
Short interest data insights for Xenon Pharmaceuticals Inc.Weekly Profit Summary & Real-Time Buy Signal Alerts - newser.com
Can Xenon Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling & AI Forecasted Stock Moves - newser.com
Technical signs of recovery in Xenon Pharmaceuticals Inc.Weekly Volume Report & Target Return Focused Picks - newser.com
Bank of New York Mellon Corp Raises Stock Position in Xenon Pharmaceuticals Inc. $XENE - Defense World
Xenon Pharmaceuticals at Jefferies London: Advancing Epilepsy and Pain Treatments - Investing.com Canada
Xenon Pharmaceuticals (NASDAQ:XENE) Given New $60.00 Price Target at JPMorgan Chase & Co. - Defense World
XENE: JP Morgan Raises Price Target to $60, Maintains Overweight Rating | XENE Stock News - GuruFocus
0.68%
1.05%
자본화:
|
볼륨(24시간):